Gene · 100616443
Papers2,197
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,197
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Anti-SARS-CoV-2 VHH and C7C peptide fused with Angiopep-2 efficiently traverse blood-brain barrier model and neutralizes virus. | Front Microbiol | 2026 | 42395902 | PubTator, text mining | PubMed |
| Phase separation of p85β modulates hepatocellular carcinoma progression through POLR1A. | Int J Biol Sci | 2026 | 42212331 | PubTator, text mining | PubMed |
| Dysregulation of SIRT1, polyamines and miRNA editing in cancer and aging. | Amino Acids | 2026 | 41863647 | PubTator, text mining | PubMed |
| RETRACTED: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling. | PLoS One | 2026 | 41811891 | PubTator, text mining | PubMed |
| FBXW7 Targets the SPT6-ΔNp63 Axis for Degradation to Inhibit Esophageal Tumorigenesis Induced by 4-Nitroquinoline N-Oxide. | MedComm (2020) | 2026 | 41799933 | PubTator, text mining | PubMed |
| Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies. | Signal Transduct Target Ther | 2026 | 41786685 | PubTator, text mining | PubMed |
| Exploring the role of microRNA-155 as a biomarker and regulatory modulator of target genes in metabolic syndrome. | SAGE Open Med | 2026 | 41777416 | PubTator, text mining | PubMed |
| Inhibiting ADAR1-Mediated Excessive Epigenetic A-to-I RNA Editing Improves the Immune Microenvironment and Increases Sensitivity to Immunotherapy in Lung Adenocarcinoma. | MedComm (2020) | 2026 | 41756256 | PubTator, text mining | PubMed |
From the Literature on Mining to Computational Verification: A Review of the Anti-Radiation Mechanisms of Sulfur Compounds in the Seeds of Lepidium apetalum Willd and Descurainia sophia (L.) Webb ex Prantl. | Int J Mol Sci | 2026 | 41751982 | PubTator, text mining | PubMed |
| STOML2 promotes hepatocellular carcinoma cell proliferation, invasion and migration by activating the PI3K/AKT signaling pathway (Review). | Oncol Lett | 2026 | 41743019 | PubTator, text mining | PubMed |
| Role of PI3K gene family as a molecular hub for regulation of growth and immunity: Potential implications for sustainable poultry production. | Poult Sci | 2026 | 41734668 | PubTator, text mining | PubMed |
| SH3 domains selectively activate the PI3 kinase through non-conventional tertiary contacts. | Commun Biol | 2026 | 41554993 | PubTator, text mining | PubMed |
| PI3K/AKT/eNOS Modulation and Angiotensin II Suppression by Dryopteris crassirhizoma Rhizome Extract: Computational and Experimental Evidence. | ACS Omega | 2026 | 41552486 | PubTator, text mining | PubMed |
| COMMD4 Drives Skin Cutaneous Melanoma Progression by Targeting PI3K-p85 to Activate PI3K-AKT. | Ann N Y Acad Sci | 2026 | 41283898 | PubTator, text mining | PubMed |
| Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy. | Int J Mol Sci | 2025 | 41778397 | PubTator, text mining | PubMed |
| Video-based Intake Gesture Recognition Using Meal-length Context. | ACM Trans Comput Healthc | 2025 | 41647333 | PubTator, text mining | PubMed |
| P21-activated kinase 4: a potent oncogene, molecular mechanisms and opportunities for targeted therapy. | Cancer Cell Int | 2025 | 41250149 | PubTator, text mining | PubMed |
| Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment. | J Virol | 2025 | 40965142 | PubTator, text mining | PubMed |
| Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies. | Discov Oncol | 2025 | 40956459 | PubTator, text mining | PubMed |
| PTEN defects in cancer, from gene to protein molecular causes and therapeutic targets. | Discov Oncol | 2025 | 40877546 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/100616443/papers